ArticleFrontiers in aging2026
Role of essential and trace elements in chronic myeloid leukemia: associations with serum trace element profiles and hematological parameters.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic myeloid leukemia is a myeloproliferative malignancy characterized by the Philadelphia chromosome with uncontrolled expansion of myeloid cells. Trace elements are essential for cellular metabolism, DNA repair, antioxidant defence, and immune regulation, and their imbalance may influence leukemogenesis and contribute to oxidative stress, immune dysregulation, and hematological alterations. Profiling trace elements may improve understanding of CML-associated trace element alterations and identify candidate biomarkers for future validation. Material and methods: A cross-sectional study at Banaras Hindu University, India, included 93 CML patients and 93 age and sex-matched healthy controls from an eastern Indian population. Serum chromium (Cr), copper (Cu), manganese (Mn), lead (Pb), cadmium (Cd), arsenic (As), iron (Fe), selenium (Se), and zinc (Zn) concentrations were measured by atomic absorption spectroscopy. Complete blood counts were performed, and data analysed using descriptive statistics, Mann-Whitney U test, Chi-square/Fisher's exact tests, and Spearman correlation analysis. Results: CML patients exhibited significantly elevated serum concentrations of Cu, Mn, Pb, Cd, and As compared with healthy controls, whereas Cr, Fe, Se, and Zn concentrations were significantly higher in healthy controls. Several trace elements showed statistically significant associations with hematological parameters, suggesting complex interactions between elemental imbalance and CML biology. Conclusion: This study strongly shows dysregulation of essential and toxic trace elements in CML. Imbalance of selenium (Se), zinc (Zn), iron (Fe), manganese (Mn), and copper (Cu) may contribute to oxidative stress, immune dysfunction, and leukemogenesis, and toxic metals may enhance genomic instability. Trace-element profiling, especially selenium-related biomarkers, may serve as candidate biomarkers associated with CML and warrant validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.